NCT00599118

Brief Summary

The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,300

participants targeted

Target at P75+ for all trials

Timeline
113mo left

Started Aug 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
Aug 2005Dec 2035

Study Start

First participant enrolled

August 1, 2005

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

January 10, 2008

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 23, 2008

Completed
27.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2035

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2035

Last Updated

September 10, 2025

Status Verified

August 1, 2025

Enrollment Period

30.4 years

First QC Date

January 10, 2008

Last Update Submit

September 8, 2025

Conditions

Atrial Fibrillation

Keywords

Atrial FibrillationGenetics

Outcome Measures

Primary Outcomes (1)

  • Genetic variants associated with atrial fibrillation

    Genome-wide association study of atrial fibrillation

    Baseline

Study Arms (2)

atrial fibrillation

Atrial fibrillation

Control

Control subjects with no atrial fibrillation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects with atrial fibrillation

You may qualify if:

  • Male or female at least 18 years old
  • Subjects with a history of or current Atrial Fibrillation

You may not qualify if:

  • Male or female at least 18 years old
  • Subjects with no history of Atrial Fibrillation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinical Foundation

Cleveland, Ohio, 44145, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

plasma, serum, buffy coat, DNA

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mina K Chung, MD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 10, 2008

First Posted

January 23, 2008

Study Start

August 1, 2005

Primary Completion (Estimated)

December 1, 2035

Study Completion (Estimated)

December 1, 2035

Last Updated

September 10, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations

US(1)